Literature DB >> 12891531

Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients.

Faten N Aberra1, James D Lewis, David Hass, John L Rombeau, Benjamin Osborne, Gary R Lichtenstein.   

Abstract

BACKGROUND & AIMS: Many patients with inflammatory bowel disease receive corticosteroids and 6-mercaptopurine/azathioprine during elective bowel surgery. We investigated the postoperative infection risk for patients undergoing elective bowel surgery who were receiving corticosteroids and/or 6-mercaptopurine/azathioprine before surgery compared with patients not receiving these medications.
METHODS: A retrospective cohort study was conducted on 159 patients with inflammatory bowel disease who underwent elective bowel surgery. There were 56 patients receiving corticosteroids alone, 52 patients receiving 6-mercaptopurine/azathioprine alone or with corticosteroids, and 51 patients receiving neither corticosteroids nor 6-mercaptopurine/azathioprine. Postoperative infectious complications to time of discharge were categorized into major and minor complications.
RESULTS: Patients receiving corticosteroids had an adjusted odds ratio for any and major infectious complications of 3.69 (95% confidence interval [CI], 1.24-10.97) and 5.54 (95% CI, 1.12-27.26), respectively. The adjusted odds ratio for patients receiving 6-mercaptopurine/azathioprine for any and major infectious complications was 1.68 (95% CI, 0.65-4.27) and 1.20 (95% CI, 0.37-3.94), respectively.
CONCLUSIONS: Preoperative use of corticosteroids in patients with inflammatory bowel disease who are undergoing elective bowel surgery is associated with an increased risk of postoperative infectious complications. 6-Mercaptopurine/azathioprine alone and the addition of 6-mercaptopurine/azathioprine for patients receiving corticosteroids was not found to significantly increase the risk of postoperative infectious complications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12891531     DOI: 10.1016/s0016-5085(03)00883-7

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  67 in total

1.  Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease.

Authors:  W J Sandborn; E V Loftus
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

Review 2.  Standards of medical treatment and nutrition in Crohn's disease.

Authors:  Britta Siegmund; Martin Zeitz
Journal:  Langenbecks Arch Surg       Date:  2004-09-23       Impact factor: 3.445

3.  Leukocyte removal therapy before surgery in ulcerative colitis.

Authors:  Toshiyuki Matsui
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

4.  Postoperative complications have little influence on long-term quality of life in Crohn's patients.

Authors:  Michael S Kasparek; Joerg Glatzle; Mario H Mueller; Andreas Schneider; Alfred Koenigsrainer; Martin E Kreis
Journal:  J Gastrointest Surg       Date:  2007-11-28       Impact factor: 3.452

5.  European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

Authors:  S P L Travis; E F Stange; M Lémann; T Oresland; Y Chowers; A Forbes; G D'Haens; G Kitis; A Cortot; C Prantera; P Marteau; J-F Colombel; P Gionchetti; Y Bouhnik; E Tiret; J Kroesen; M Starlinger; N J Mortensen
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

Review 6.  Surgical treatment of ulcerative colitis in the biologic therapy era.

Authors:  Alberto Biondi; Marco Zoccali; Stefano Costa; Albert Troci; Ettore Contessini-Avesani; Alessandro Fichera
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

7.  When should we add a diverting loop ileostomy to laparoscopic ileocolic resection for primary Crohn's disease?

Authors:  Yong Sik Yoon; Luca Stocchi; Stefan Holubar; Alexandra Aiello; Sherief Shawki; Emre Gorgun; Scott R Steele; Conor P Delaney; Tracy Hull
Journal:  Surg Endosc       Date:  2020-05-28       Impact factor: 4.584

Review 8.  Preoperative optimization of crohn disease.

Authors:  Amit Sharma; Bertram T Chinn
Journal:  Clin Colon Rectal Surg       Date:  2013-06

Review 9.  Biologic therapy and surgery for crohn disease.

Authors:  E Carter Paulson
Journal:  Clin Colon Rectal Surg       Date:  2013-06

10.  Granulo-monocyto apheresis is more effective in mild ulcerative colitis than in moderate to severe disease.

Authors:  Chiara De Cassan; Edoardo Savarino; Piero Marson; Tiziana Tison; Giorgia Hatem; Giacomo Carlo Sturniolo; Renata D'Incà
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.